EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Real-world comparison of one- versus two-injection start regimens of aripiprazole once-monthly in bipolar disorder: implications for relapse-related outcomes

Mustafa Kurt iD, Ali Taşdemir iD

Nordic Journal of Psychiatry · 18.08.2026 · 80 (6) · 395-403

DOI: 10.1080/08039488.2026.2699319 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nordic Journal of Psychiatry, online erschienen am 07.07.2026. Verfasst von Mustafa Kurt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Mental Health and Diseases, Karadeniz Technical University, Trabzon, Türkiye. Hauptthemen laut MEDLINE: Bipolar Disorder, Aripiprazole, Antipsychotic Agents. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The standard one-injection start (OIS) regimen of aripiprazole once-monthly (AOM) requires a 14-day oral overlap, which may present practical challenges in routine care. This study evaluated whether the accelerated two-injection start (TIS) strategy, which eliminates oral overlap, affects 1-year real-world outcomes in patients with bipolar disorder (BD).

Methods

This retrospective observational study included 132 inpatients with Bipolar I disorder hospitalized for an acute manic episode (OIS: n = 88; TIS: n = 44) initiated on AOM between January and December 2024. Primary outcomes were 1-year rehospitalization and emergency room (ER) visits. Exploratory analyses examined relapse-related outcomes, timing of initiation, and baseline illness severity.

Results

Baseline and acute-phase characteristics were comparable between groups. Multivariable models confirmed the TIS regimen did not significantly increase the hazard of 1-year rehospitalization (aHR: 0.71, p = 0.435) or ER visits (aHR: 0.76, p = 0.378) compared to OIS. Among patients who relapsed, TIS was associated with fewer recurrent ER visits (p = 0.031) and a longer time to first ER visit (93.5 vs. 40.0 days). Exploratory analyses showed numerically lower ER utilization rates for the TIS regimen when initiated early (≤7 days) and among patients with higher baseline illness severity.

Conclusions

The TIS regimen appears to be a feasible and safe alternative to OIS in BD, without compromising 1-year clinical outcomes or increasing adjunctive medication use. Exploratory findings suggested a potential trend toward a less intensive relapse course and delayed acute psychiatric service utilization among patients receiving TIS. Given the exploratory nature of these analyses, these observations require confirmation in larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderAripiprazoleAntipsychotic AgentsHumansFemaleMaleRetrospective StudiesAdultRecurrenceMiddle AgedDrug Administration SchedulePatient Readmission

Stichwörter der Autor:innen

Aripiprazole once-monthlybipolar disorderlong-acting injectableone-injection starttwo-injection start

Substanzen

AripiprazoleAntipsychotic Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Mental Health and Diseases, Karadeniz Technical University, Trabzon, Türkiye.
  • Adana Dr. Ekrem Tok Mental Health and Diseases Hospital, Adana, Türkiye.

ORCID-Profile: Mustafa Kurt, Ali Taşdemir

Zitieren

APA

Kurt, M., & Taşdemir, A. (2026). Real-world comparison of one- versus two-injection start regimens of aripiprazole once-monthly in bipolar disorder: implications for relapse-related outcomes. Nordic Journal of Psychiatry, 80(6), 395-403. https://doi.org/10.1080/08039488.2026.2699319

Vancouver

Kurt M, Taşdemir A. Real-world comparison of one- versus two-injection start regimens of aripiprazole once-monthly in bipolar disorder: implications for relapse-related outcomes. Nordic Journal of Psychiatry. 2026;80(6):395-403. doi:10.1080/08039488.2026.2699319

BibTeX
@article{Kurt2026,
  author = {Kurt, Mustafa and Taşdemir, Ali},
  title = {Real-world comparison of one- versus two-injection start regimens of aripiprazole once-monthly in bipolar disorder: implications for relapse-related outcomes},
  journal = {Nordic Journal of Psychiatry},
  year = {2026},
  volume = {80},
  number = {6},
  pages = {395--403},
  doi = {10.1080/08039488.2026.2699319}
}
Kostenlos starten →